Recipharm launches Recipharm Inhalation Solutions™ as its end-to-end offering for inhalation products
Recipharm, the contract development and manufacturing organisation (CDMO), has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.
Recipharm Inhalation Solutions™, which launched at Respiratory Drug Delivery Europe 2019, May 7 – 10, Lisbon, Portugal, offers pharmaceutical companies a seamless outsourcing service for inhalation products, including metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nasal sprays.
The offering follows the acquisition of Sanofi’s inhalation manufacturing business in Holmes Chapel, UK in June 2018, which has specialised in the manufacture of inhalation drug products for over 40 years. The facility is supported by Recipharm’s inhalation development expertise in Research Triangle Park, North Carolina, US.
Commenting on the announcement, Shabbir Mostafa, Global Key Account Director – Inhalations at Recipharm said: “Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business. In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating for instance central nervous system conditions. This is making inhalation an interesting area for drug developers”.
“The Recipharm team has a long history in inhalation drug product development and manufacturing. This heritage, combined with market demand, made the launch of Recipharm Inhalation Solutions™ a logical step for us”.
“Our team has the depth of knowledge required to overcome the challenges associated with developing and manufacturing these types of products. We also understand the hurdles on the path to commercialisation and are well placed to manage complexity and risk along this journey.”
Recipharm Inhalation Solutions™ includes dedicated analytical services for inhalation products, including comprehensive extractable and leachable expertise. A dedicated pilot facility composed of several suites which can replicate commercial processes also assists with the seamless transfer of projects from small to large scale production. In addition, Recipharm has the technical ability to work with different devices, combinations, APIs and suspension formulations.
For more information, visit www.recipharm.com/solutions/recipharm-inhalation-solutions
Shabbir Mostafa, Key Account Director for Inhalation, firstname.lastname@example.org, +44 7753469835
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com